U.S., Nov. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07924137) titled 'Acute Kidney Injury and Intermittent Dialysis Dose' on Nov. 03.
Brief Summary: Intermittent hemodialysis (IHD) is the first-line kidney replacement modality in 50% of severe acute kidney injury (AKI) cases in French intensive care units (ICUs). It clears uremic toxins and restores acid-base and fluid-sodium balance, but the osmotic imbalance it induces can cause or worsen hemodynamic and neurological failure. Dialysis dose is a major prognostic issue, yet the optimal target and the best tools to quantify it in AKI remain debated.
Kt/Vd, validated in chronic kidney disease, is largely biased in AKI because the urea distribution volu...